immunologic monitoring

Summary

Summary: Testing of immune status in the diagnosis and therapy of cancer, immunoproliferative and immunodeficiency disorders, and autoimmune abnormalities. Changes in immune parameters are of special significance before, during and following organ transplantation. Strategies include measurement of tumor antigen and other markers (often by RADIOIMMUNOASSAY), studies of cellular or humoral immunity in cancer etiology, IMMUNOTHERAPY trials, etc.

Top Publications

  1. ncbi Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring
    Daniel E Speiser
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Immunother 27:298-308. 2004
  2. ncbi Immunologic monitoring
    Maria P Hernandez-Fuentes
    Department of Immunology, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN, UK
    Immunol Rev 196:247-64. 2003
  3. ncbi Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy
    Ulrich Keilholz
    UKBF Free University, Berlin, Germany
    J Immunother 25:97-138. 2002
  4. ncbi Immune monitoring of T-cell responses in cancer vaccine development
    Ulrich Keilholz
    Charite, Campus Benjamin Franklin, Department of Medicine III, Free University Berlin, Germany
    Clin Cancer Res 12:2346s-2352s. 2006
  5. pmc Toward the harmonization of immune monitoring in clinical trials: quo vadis?
    C M Britten
    Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
    Cancer Immunol Immunother 57:285-8. 2008
  6. pmc The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays
    C M Britten
    Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
    Cancer Immunol Immunother 57:289-302. 2008
  7. ncbi Hybrid-cell vaccines for cancer immune therapy
    Uwe Trefzer
    Department of Dermatology and Allergy, Charité Humboldt University Medical School, Schumannstrase, 20 21, 10117, Berlin, Germany
    Mol Biotechnol 25:63-9. 2003
  8. ncbi Antigen-specific cancer vaccines
    Ulrich Keilholz
    Department of Medicine III, Charite Campus Benjamin Franklin, Berlin, Germany
    Recent Results Cancer Res 176:213-8. 2007
  9. ncbi Pre- and post-transplant monitoring of soluble CD30 levels as predictor of acute renal allograft rejection
    Dong Wang
    Organ Transplant Institute, Fuzhou General Hospital, No 156 Xi erhuan North Road, Fuzhou, 350025, China
    Transpl Immunol 17:278-82. 2007
  10. ncbi Monitoring of anti-HLA and anti-Major histocompatibility complex class I related chain A antibodies in living related renal donor transplantation
    A Panigrahi
    Department of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi, India
    Transplant Proc 39:759-60. 2007

Research Grants

  1. Phase I Trial with Two HER-2 B Cell Epitope Vaccine in Patients with Solid Tumors
    PRAVIN T P contact KAUMAYA; Fiscal Year: 2010
  2. Immunoregulation and immunotherapy of breast cancer
    Robert H Vonderheide; Fiscal Year: 2012
  3. Novel Strategies for Brain Tumor Therapy
    Ian F Pollack; Fiscal Year: 2012
  4. Eastern Cooperative Oncology Group (Main Institution)
    JOHN MUNN KIRKWOOD; Fiscal Year: 2013
  5. SPORE in Skin Cancer
    JOHN MUNN KIRKWOOD; Fiscal Year: 2013
  6. CANCER CENTER SUPPORT GRANT
    Michelle M Le Beau; Fiscal Year: 2013
  7. DISSECTING THE IMMUNE BASIS OF DISEASE AND THERAPY
    Nitin J Karandikar; Fiscal Year: 2013
  8. Host-tumor cell interaction in myeloma: therapeutic applications
    Kenneth C Anderson; Fiscal Year: 2013
  9. Stem Cell-Engineered Tumor Immunity in Man
    David Baltimore; Fiscal Year: 2013
  10. Predicting immune responses that correlate with protection against tuberculosis
    JENNIFER JEAN LINDERMAN; Fiscal Year: 2013

Detail Information

Publications238 found, 100 shown here

  1. ncbi Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring
    Daniel E Speiser
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Immunother 27:298-308. 2004
    ..Comparable results were obtained with ELISPOT assays. In conclusion, this approach is well suited to assess T-cell responses as biologic endpoints in clinical vaccine studies...
  2. ncbi Immunologic monitoring
    Maria P Hernandez-Fuentes
    Department of Immunology, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN, UK
    Immunol Rev 196:247-64. 2003
    ..Of course sensitive, accurate and specific immunologic monitoring has applications well beyond the field of transplantation.
  3. ncbi Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy
    Ulrich Keilholz
    UKBF Free University, Berlin, Germany
    J Immunother 25:97-138. 2002
    ..At present, assays appear to be most useful as measures of vaccine potency. Careful immune monitoring in association with larger scale clinical trials ultimately may enable the correlation of monitoring results with clinical benefit...
  4. ncbi Immune monitoring of T-cell responses in cancer vaccine development
    Ulrich Keilholz
    Charite, Campus Benjamin Franklin, Department of Medicine III, Free University Berlin, Germany
    Clin Cancer Res 12:2346s-2352s. 2006
    ....
  5. pmc Toward the harmonization of immune monitoring in clinical trials: quo vadis?
    C M Britten
    Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
    Cancer Immunol Immunother 57:285-8. 2008
  6. pmc The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays
    C M Britten
    Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
    Cancer Immunol Immunother 57:289-302. 2008
    ..Such "two-step" inter-laboratory projects could define rational bases for accepted international guidelines and thereby lead to the harmonization of the techniques used for immune monitoring...
  7. ncbi Hybrid-cell vaccines for cancer immune therapy
    Uwe Trefzer
    Department of Dermatology and Allergy, Charité Humboldt University Medical School, Schumannstrase, 20 21, 10117, Berlin, Germany
    Mol Biotechnol 25:63-9. 2003
    ....
  8. ncbi Antigen-specific cancer vaccines
    Ulrich Keilholz
    Department of Medicine III, Charite Campus Benjamin Franklin, Berlin, Germany
    Recent Results Cancer Res 176:213-8. 2007
    ....
  9. ncbi Pre- and post-transplant monitoring of soluble CD30 levels as predictor of acute renal allograft rejection
    Dong Wang
    Organ Transplant Institute, Fuzhou General Hospital, No 156 Xi erhuan North Road, Fuzhou, 350025, China
    Transpl Immunol 17:278-82. 2007
    ..Therefore, sCD30 level may be a good marker of increased alloreactivity and of significant predictive value. It's necessary to monitor the variation of sCD30 in the early period post-transplant...
  10. ncbi Monitoring of anti-HLA and anti-Major histocompatibility complex class I related chain A antibodies in living related renal donor transplantation
    A Panigrahi
    Department of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi, India
    Transplant Proc 39:759-60. 2007
    ..035 and P = .001, respectively) as compared to the nonsensitized group. The study illustrated that posttransplant monitoring antibodies to both MICA as well as HLA could be good predictors of renal allograft failure...
  11. ncbi Serial monitoring of immunological parameters following human hand transplant
    Xiao Fei Zheng
    Orthopaedics Department, Guangzhou, Liuhuaqiao Hospital, Guangzhou, China
    Clin Transplant 18:119-23. 2004
    ..Although early successes have been achieved in human hand transplant, the changes of immunological parameters in the recipients and their relations to clinical events were not yet known...
  12. ncbi Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy
    Mysore S Anil Kumar
    Division of Transplantation, Department of Surgery and Transplantation, Drexel University College of Medicine and Hahnemann University Hospital, Philadelphia, PA 19102, USA
    Transplantation 80:807-14. 2005
    ..This prospective study compared the safety and efficacy of steroid avoidance in tacrolimus (TAC)/mycophenolate mofetil (MMF) and TAC/sirolimus (SRL) combinations in kidney transplantation...
  13. ncbi Current approaches in dendritic cell generation and future implications for cancer immunotherapy
    Sandra Tuyaerts
    Laboratory of Molecular and Cellular Therapy, Department of Physiology and Immunology, Medical School of the Vrije Universiteit Brussel, Laarbeeklaan 103 E, 1090, Brussels, Belgium
    Cancer Immunol Immunother 56:1513-37. 2007
    ..Here, we review the recent developments in clinical DC generation, antigen loading methods and immunomonitoring approaches for DC-based trials...
  14. ncbi Mimotopes of tumor-associated T-cell epitopes for cancer vaccines determined with combinatorial peptide libraries
    Tumenjargal Sherev
    Department of Dermatology and Allergy, Medical Faculty Charité, Humboldt University, Schumannstrasse 20 21, 10117, Berlin, Germany
    Mol Biotechnol 25:53-61. 2003
    ....
  15. ncbi Unusual presentation of herpes virus infections in renal transplant recipients exposed to high mycophenolic acid plasma concentrations
    P J H Smak Gregoor
    Department of Internal Medicine, Room D 412, Erasmus Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Transpl Infect Dis 5:79-83. 2003
    ..High MPA levels may reflect over-immunosuppression resulting in infectious complications...
  16. ncbi Results of the first phase I/II clinical vaccination trial with direct injection of mRNA
    Benjamin Weide
    Department of Dermatology, Institute for Cell Biology, University of Tubingen, Germany
    J Immunother 31:180-8. 2008
    ..However, a demonstration of clinical effectiveness of direct injection of copy mRNA for antitumor immunotherapy was not shown in this study and must be evaluated in subsequent trials...
  17. ncbi Interleukin-6, interleukin-8, and interleukin-10 in kidney transplantation: improved risk strategy?
    R Diller
    Surgical Research, Department of General Surgery, Muenster University Hospital, Muenster, Germany
    Transplant Proc 35:1333-7. 2003
  18. ncbi Sialyl Lewis(x) monitoring as an early detector of B-cell-dependent rejection
    Hideki Ishida
    Department of Urology, Tokyo Women s Medical University, 8 1 Kawada cho, Shinjuku ku, Tokyo 162 0054, Japan
    Transplant Proc 34:1760-2. 2002
  19. ncbi The number of peripheral CD4CD25 cells and early postoperative episodes in renal transplantation
    S Satoh
    Department of Urology, Akita University School of Medicine, 1 1 1 Hondo, Akita 010 8543, Japan
    Transplant Proc 34:1755-6. 2002
  20. ncbi Effect of mycophenolate mofetil regimen on peripheral blood lymphocyte subsets in kidney transplant recipients
    J A Bravo Soto
    Nephrology Services of Virgen de las Nieves University Hospital, Grenada, Spain
    Transplant Proc 35:1355-9. 2003
    ..Due to the selective antiproliferative effect of mycophenolate mofetil (MMF) on lymphocytes, our goal was to determine whether MMF modulates peripheral blood lymphocyte subsets (PBLS) in kidney allograft patients...
  21. ncbi Immunological monitoring of calcineurin inhibitors for predicting cytomegalovirus infection in kidney transplant recipients
    Lionel Couzi
    Service de Nephrologie, CHU Bordeaux, Hopital Pellegrin, CNRS UMR 5164, 146 rue Leo Saignat, Universite Bordeaux 2, INSERM U897, 146, rue Leo Saignat, Bordeaux, France
    Transplantation 86:1060-7. 2008
    ..Measurement of the biological effects of CNI could provide clues to identify overimmunosuppressed kidney transplant recipients (KTR) who would subsequently develop CMV infection...
  22. ncbi Preliminary evaluation of the new TACR flex method versus MEIA method in the therapeutic monitoring of tacrolimus in organ transplantation
    A Bachetoni
    Department of General Surgery, Paride Stefanini, Laboratory of Clinical Pathology, University of Sapienza, Roma, Italy
    Transplant Proc 39:2008-9. 2007
    ..The TACR Flex Dimension method provided a higher automation level and therefore a lower incidence of preanalytical errors and a lower turnaround time...
  23. ncbi Immune profiling: molecular monitoring in renal transplantation
    Steven C Hoffmann
    Transplantation Section, Transplantation and Autoimmunity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20889, USA
    Front Biosci 8:e444-62. 2003
    ..Suggestions for the adaptation of these methods for therapeutic intervention will be given. We propose that clinical transplantation should proceed in close step with modern molecular diagnostics...
  24. ncbi Spontaneous operational tolerance after immunosuppressive drug withdrawal in clinical renal allotransplantation
    Joanna Ashton-Chess
    INSERM, U643, Nantes, France
    Transplantation 84:1215-9. 2007
    ..Collaborative efforts through international networks, together with the application of newer and more powerful technologies to diagnostic, prognostic, and mechanistic research, may help transplanters to achieve this goal...
  25. ncbi [Development of immunotherapy for cancer: lessons from melanoma research]
    Yutaka Kawakami
    Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine
    Nihon Rinsho Meneki Gakkai Kaishi 27:87-98. 2004
    ..The translational research performed on melanoma, would facilitate development of immunotherapy for other cancers...
  26. ncbi Cyclosporin exposure correlates with 1 year graft function and histological damage in renal transplanted patients
    Salvatore Di Paolo
    Department of Emergency and Organ Transplant, Division of Nephrology, University of Bari, Policlinico, Piazza Giulio Cesare 11, I 70124 Bari, Italy
    Nephrol Dial Transplant 19:2107-12. 2004
    ..The impact of C(2) monitoring on long-term kidney graft function, independent from AR risk, is still unclear, however, and it was assessed in the present study...
  27. ncbi Monitoring anti-HLA Class I IgG antibodies in renal transplant recipients
    E Aragão
    Nephrology Division, Sao Paulo Federal University, Kidney and Hypertension Hospital, Sao Paulo, SP, Brazil
    Transplant Proc 36:836-7. 2004
    ..4%); infarction (25%); and no rejection (12.5%). We observed a high incidence of anti-HLA class I IgG antibodies during acute tubular necrosis, borderline changes, acute rejection types IIB and III, and chronic allograft nephropathy...
  28. ncbi The ratio of interferon-gamma and interleukin-10 producing donor-specific cells as an in vitro monitoring tool for renal transplant patients
    Daniëlle E M van den Boogaardt
    Department of Immunohematology and Blood Transfusion, Leiden University Medical Centre, Leiden, The Netherlands
    Transplantation 82:844-8. 2006
    ..The ratio of IFN-gamma/IL-10 producing cells showed to be the best tool to discriminate between nonrejecting patients and rejecting patients...
  29. ncbi Use of an immune function assay to monitor immunosuppression for treatment of post-transplant lymphoproliferative disorder
    Amitabh Gautam
    Division of Organ Transplantation, Rhode Island Hospital, Providence, RI 02903, USA
    Pediatr Transplant 10:613-6. 2006
    ..Later, when the cell-mediated immune response increased, with negative viral load, immunosuppression was gradually increased utilizing the assay to adjust dosing. Presently, there are no signs of PTLD and renal function remains normal...
  30. ncbi Use of an immune function assay to monitor immunosuppression
    Paul Grimm
    Pediatr Transplant 10:533-5. 2006
  31. ncbi Cyclosporine lymphocyte maximum level monitoring in de novo kidney transplant patients: a prospective study
    A G Barbari
    Nephrology and Transplantation Unit, Rizk Hospital, Beirut, Lebanon
    Exp Clin Transplant 4:400-5. 2006
    ..To determine prospectively the temporal variations of cyclosporine-A lymphocyte maximum level, whole blood maximum concentration, and total lymphocyte count in patients with de novo kidney transplantation...
  32. ncbi Interferon-gamma and cancer immunoediting
    Gavin P Dunn
    Department of Pathology and Immunology, Center for Immunology, Washington University School of Medicine, St Louis, MO 63110, USA
    Immunol Res 32:231-45. 2005
    ..Our current work focuses on defining the molecular mechanisms that underlie cancer immunoediting and exploring the implications of this process for cancer immunotherapy...
  33. ncbi Anti-HLA antibodies in kidney transplanted patients
    D Maccarone
    Immunohematology and Tissue Typing Regional Center, Regional Transplant Centre, L Aquila, Italy
    Transplant Proc 37:2459-60. 2005
    ..We cannot exclude the possibility that antibodies produced by some patients may not be detectable because they are attached to the graft...
  34. ncbi [Dynamic observation of serum cytokines in patients receiving hand transplantation]
    X Zheng
    Department of Orthopaedics, Liuhuachiao Hospital, Guangzhou 510515, China
    Zhonghua Wai Ke Za Zhi 39:789-91. 2001
    ..Hand transplantation does not elicit significant immune rejection. The dynamic determination of cytokines helps judge the prognosis and diagnosis of rejection in hand transplantation...
  35. ncbi Tolerance assays: measuring the unknown
    Kenneth A Newell
    The Emory Transplant Center and Department of Surgery, Emory University, Atlanta, Georgia 30345, USA
    Transplantation 81:1503-9. 2006
    ..Validation of "tolerance" assays will be critical for the safe development of tolerance regimens in humans...
  36. ncbi Comparison of the reintroduced MEIA assay with HPLC-MS/MS for the determination of whole-blood sirolimus from transplant recipients
    Raymond G Morris
    Department of Cardiology and Clinical Pharmacology, The Queen Elizabeth Hospital, Woodville, Australia
    Ther Drug Monit 28:164-8. 2006
    ..In selected patients where difficult clinical issues arise, reference to a specific chromatographic method may be required...
  37. ncbi Quantitative detection of changes in cytokine gene expression in peripheral blood mononuclear cells correlates with and precedes acute rejection in renal transplant recipients
    Paul J Gibbs
    Wessex Renal and Transplant Unit, Queen Alexandra Hospital, Cosham, Portsmouth, UK
    Transpl Immunol 14:99-108. 2005
    ..This study has identified two cytokines (IL-4 and TNF-alpha) whose gene expression patterns differentiate between rejecting and non-rejecting renal transplant recipients making immunological monitoring possible...
  38. ncbi T-cell responses of vaccinated cancer patients
    Pierre G Coulie
    Cellular Genetics Unit, Christian de Duve Institute of Cellular Pathology, Universite de Louvain, Avenue Hippocrate 74, UCL 7459, B 1200 Brussels, Belgium
    Curr Opin Immunol 15:131-7. 2003
    ..However, a correlation between these T-cell responses and the tumor regressions has not yet been established. It appears that some patients display tumor regression with an unexpectedly low frequency of anti-vaccine T cells...
  39. ncbi C0 or C2 driven cyclosporine monitoring in long-term pediatric kidney transplant recipients: is there any threat for chronic rejection development?
    Mariano Ferraresso
    Division of Vascular Surgery and Kidney Transplantation, Ospedale Maggiore, Policlinico, IRCCS, Milan, Italy
    Pediatr Transplant 9:328-31. 2005
    ..The C2 determination should be considered as the gold standard for cyclosporine monitoring in long-term pediatric recipients...
  40. ncbi Graft survival and immune regulation of pancreas allograft recipients induced with thymoglobulin, sirolimus, and cyclosporine
    R J Knight
    Division of Immunology and Organ Transplantation, University of Texas Medical School, Houston, Texas 77030, USA
    Transplant Proc 37:1280-2. 2005
    ..Our objective was to determine the impact of thymoglobulin-sirolimus-cyclosporine immunosuppression on the alloimmune response of pancreas-kidney transplant recipients...
  41. ncbi Cell mediated immunity (CMI) and post transplant viral infections--role of a functional immune assay to titrate immunosuppression
    A Gautam
    Division of Organ Transplantation, Rhode Island Hospital, Providence, Rhode Island 02903, USA
    Int Immunopharmacol 6:2023-6. 2006
    ..The ImmuKnow assay of CMI can be used to titrate initial immunosuppression reduction and its subsequent increase, in patients with viral infection after transplantation...
  42. ncbi Chronic allograft nephropathy--immunologic and nonimmunologic factors
    Mirosław Banasik
    Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Poland
    Ann Transplant 11:7-10. 2006
    ..Additionally effective management by hypertension and hyperlipidemia is essential...
  43. ncbi Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein
    Yi Zhang
    Ludwig Institute for Cancer Research, Brussels Branch and Cellular Genetics Unit, Universite de Louvain, Brussels, Belgium
    J Immunol 174:2404-11. 2005
    ..The 13 anti-MAGE-3 clones, which corresponded to five different TCR clonotypes, recognized the same peptide presented by HLA-DR1...
  44. ncbi Efficacy of IgM anti-blood type antibody monitoring by enzyme-linked immunosorbent assay after renal transplantation across the blood barrier: high-dose immunoglobulin administration blocks IgM rather than IgG anti-blood type antibodies
    H Ishida
    Department of Urology, Tokyo Women s Medical University, Tokyo, Japan
    Transplant Proc 36:2178-81. 2004
    ..Blocking of IgM seems to play an important role in improving ABO-incompatible grafts...
  45. ncbi [Study of the correlation between drug exposure and blood concentration during cyclosporine microemulsion absorption phase in Chinese adult liver transplant recipients]
    Geng Chen
    Hepatobiliary Surgery Institute of Chinese P L A, Southwest Hospital, Third Military Medical University, Chongqing 400038, China
    Zhonghua Gan Zang Bing Za Zhi 12:328-30. 2004
    ....
  46. ncbi ImmuKnow: a new parameter in immune monitoring of pediatric liver transplantation recipients
    Moshe Israeli
    Tissue Typing Laboratory, Rabin Medical Center, Petach Tikva, Israel
    Liver Transpl 14:893-8. 2008
    ..It serves as a reliable and unique parameter of the cellular immune function. We conclude that the ImmuKnow assay, together with existing clinical tools, may allow for the immune monitoring of pediatric liver recipients...
  47. ncbi Monitoring immune function during tacrolimus tapering in small bowel transplant recipients
    Adriana Zeevi
    Thomas E Starzl Transplant Institute, University of Pittsburgh Medical Center, Division of Transplant Surgery, Biomedical Science Tower, Pittsburgh, PA 15261, USA
    Transpl Immunol 15:17-24. 2005
    ....
  48. ncbi Expression of HLA molecules on peripheral blood lymphocytes: a useful monitoring parameter in cardiac transplantation
    R M Blanco-Garcia
    Immunology, University Hospital Virgen de la Arrixaca, Murcia, Spain
    Transplant Proc 39:2362-4. 2007
    ..Monitoring the expression of HLA molecules on peripheral blood lymphocytes may represent an easy, noninvasive practice to individualize immunosuppressive therapy...
  49. ncbi New aspect of immunosuppressive treatment in liver transplantation. How could you induce tolerance in liver transplantation?
    Severine Beaudreuil
    Department of Nephrology, IFRNT University Hospital of Kremlin Bicetre, 78 Avenue du General LeClerc, 94275 Le Kremlin Bicetre cedex, France
    Transpl Immunol 17:98-107. 2007
    ..We describe here current experience in liver and liver-kidney transplantation, the mechanism of tolerance and the immunosuppressive strategy used in liver transplantation...
  50. ncbi Therapeutic monitoring of mycophenolate mofetil in organ transplant recipients: is it necessary?
    Michel Mourad
    Department of Kidney and Pancreas Transplantation, University Hospital Saint Luc, Universite Catholique de Louvain, Brussels, Belgium
    Clin Pharmacokinet 41:319-27. 2002
    ..However, further studies are mandatory to draw the best guidelines in order to achieve higher levels of evidence that MPA-TDM may improve patient outcome...
  51. pmc Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia
    Bipin N Savani
    Stem Cell Allogeneic Transplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bldg 10, Hatfield CRC, Bethesda, MD 20892 1202, USA
    Blood 107:1688-95. 2006
    ..These results suggest that transplanted CD34 cell doses greater than 5 x 10(6)/kg may improve outcomes by increasing the early recovery of NK cells...
  52. ncbi [Optimization of cancer immunotherapy by controlling immune cell trafficking and biodistribution]
    Naoki Okada
    Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Osaka University, Yamadaoka, Suita City, Japan
    Yakugaku Zasshi 127:327-39. 2007
    ..This review introduces our approaches that employ an Arg-Gly-Asp (RGD) fiber-mutant adenovirus vector encoding the chemokine or chemokine receptor gene in cancer immunotherapy...
  53. pmc Development of tolerogenic strategies in the clinic
    Stuart J Knechtle
    Department of Surgery, University of Wisconsin Medical School, H4 766 Clinical Science Center, Madison, 53792 7375, USA
    Philos Trans R Soc Lond B Biol Sci 360:1739-46. 2005
    ..This review will summarize efforts to date, particularly focusing on kidney transplantation...
  54. ncbi A practical approach to immune monitoring in kidney transplantation
    E Rodrigo
    Service of Nephrology, Hospital Marques de Valdecilla, Universidad de Cantabria, Santander, Spain
    Minerva Urol Nefrol 59:337-52. 2007
    ....
  55. ncbi Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring
    H Openshaw
    Department of Neurology, City of Hope National Medical Center, Duarte, California 91010, USA
    Biol Blood Marrow Transplant 6:563-75. 2000
    ..Further studies and longer follow-up would be needed to determine the significance of new lymphocyte proliferative responses after SCT and the overall effect of this treatment on the natural history of MS...
  56. pmc Sensitivity and specificity of tritiated thymidine incorporation and ELISPOT assays in identifying antigen specific T cell immune responses
    Vivian Goodell
    Center for Translational Medicine in Women s Health, 2nd Floor, 815 Mercer Street, Box 358050, University of Washington, Seattle, WA 98109 USA
    BMC Immunol 8:21. 2007
    Standardization of cell-based immunologic monitoring is becoming increasingly important as methods for measuring cellular immunity become more complex...
  57. ncbi A Ca(2+)-binding protein with numerous roles and uses: parvalbumin in molecular biology and physiology
    Syed Hasan Arif
    Section of Genetics, Department of Zoology, Aligarh Muslim University, Aligarh, UP, India
    Bioessays 31:410-21. 2009
    ..Hence, PVs appear to be amazingly useful candidate proteins regulating a variety of cellular functions through action on Ca2+ flux management...
  58. ncbi [Initial results of a controlled study of small cell and squamous epithelial bronchial cancer: polychemotherapy and interferons]
    P Zabel
    Medizinische Klinik, Borstel
    Pneumologie 44:586-7. 1990
    ..In contrast, alveolar macrophages as part of local immunity show a decrease in the spontaneous and LPS-induced production of IL-1...
  59. ncbi Immunological and inflammatory features of Kaposi's sarcoma and other Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8-associated neoplasias
    Giovanni Riva
    Department of Oncology, Hematology and Respiratory Diseases, University of Modena and Reggio Emilia, Modena, Italy
    AIDS Rev 12:40-51. 2010
    ..inflammatory profile with protective activity against Kaposi's sarcoma outbreaks, will eventually foster immunologic monitoring protocols during the follow-up of AIDS and posttransplant patients, either preventing or treating human ..
  60. ncbi Organ transplantation in Bulgaria
    Elissaveta Naumova
    Central Laboratory of Clinical Immunology, University Hospital Alexandrovska, 1 Georgy Sofiisky Street, Sofia, 1431, Bulgaria
    Cell Tissue Bank 9:337-42. 2008
    ..84, P<0.001) and graft loss (Chi-square=20.283, P<0.001). Based on the experience in our transplant center a strategy for improvement of long-term renal graft survival was developed and implemented...
  61. ncbi Systemic administration of cellular interleukin-10 can exacerbate cardiac allograft rejection in mice
    S Qian
    Thomas E Starzl Transplantation Institute and Department of Surgery, University of Pittsburgh, Pennsylvania 15213, USA
    Transplantation 62:1709-14. 1996
    ..b>Immunologic monitoring of transplanted mice revealed that IL-10 treatment (100 microg/d, i.p...
  62. pmc Proteomic signatures in plasma during early acute renal allograft rejection
    Gabriela V Cohen Freue
    Prevention of Organ Failure PROOF Centre of Excellence, Vancouver, British Columbia, Canada
    Mol Cell Proteomics 9:1954-67. 2010
    ..This study provides evidence that protein concentrations in plasma may provide a relevant measure for the occurrence of BCAR and offers a potential tool for immunologic monitoring.
  63. pmc Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testing
    Elaine Coustan-Smith
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA
    Best Pract Res Clin Haematol 23:347-58. 2010
    ..In this article, we discuss methodologic issues related to the immunologic monitoring of MRD and the evidence supporting its clinical significance, and compare the advantages and limitations ..
  64. ncbi Immunological monitoring in workers occupationally exposed to asbestos
    Silvia Ilavska
    Research Base of the Slovak Medical University, Institute of Preventive and Clinical Medicine, Department of Clinical Immunology, Limbova 12, 833 01 Bratislava, Slovak Republic
    Toxicology 206:299-308. 2005
    ....
  65. ncbi Comparative evaluation of 'TaqMan' RT-PCR and RT-PCR ELISA for immunological monitoring of renal transplant recipients
    Paul J Gibbs
    Wessex and Renal Transplant Unit, St Mary s Hospital, Milton Road, Portsmouth, UK
    Transpl Immunol 11:65-72. 2003
    ..Therefore, real time quantitative RT-PCR technology may be useful in monitoring the immunological status of these patients in the early post-operative period...
  66. ncbi No Immune Risk Profile among individuals who reach 100 years of age: findings from the Swedish NONA immune longitudinal study
    Jan Strindhall
    Department of Natural Science and Biomedicine, School of Health Sciences, Jonkoping University, Box 1026, 551 11 Jönköping, Sweden
    Exp Gerontol 42:753-61. 2007
    ....
  67. ncbi Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Asahi machi, Kurume, Japan
    Prostate 60:32-45. 2004
    ..Additive antitumor effects could be achieved by combination of immunotherapy and cytotoxic agents with no or minimum suppression...
  68. ncbi Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings
    David M Moore
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
    J Acquir Immune Defic Syndr 43:436-9. 2006
    ..The performance of immunologic monitoring for this purpose has not been evaluated, however.
  69. ncbi Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses
    J L Marshall
    Georgetown University Medical Center, Vincent T Lombardi Cancer Center, Washington, DC 20007, USA
    J Clin Oncol 18:3964-73. 2000
    ..This trial sought to determine, for the first time, the validity in human vaccinations of using two different recombinant vaccines in diversified prime-and-boost regimens to enhance T-cell responses to a tumor antigen...
  70. ncbi Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer
    B L Gause
    Division of Cancer Treatment, National Cancer Institute, Bethesda, MD, USA
    J Clin Oncol 14:2234-41. 1996
    ..The purpose of this study is to define the maximum-tolerated dosage (MTD) of IL-2 and interferon alfa-2a (IFN alpha-2a) that can be administered chronically on an outpatient basis...
  71. ncbi Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens
    R Weimer
    Department of Internal Medicine, University Clinic of Giessen and Marburg, Germany
    Am J Transplant 6:1865-74. 2006
    ..Our data suggest that elevated sCD30 and neopterin predict graft deterioration by CAN. Tacr effectively downregulates these responses and might be of advantage in patients with elevated sCD30 or neopterin...
  72. ncbi The immune risk profile is associated with age and gender: findings from three Swedish population studies of individuals 20-100 years of age
    Anders Wikby
    Department of Natural Science and Biomedicine, School of Health Sciences, Jonkoping University, Box 1026, 551 11 Jönköping, Sweden
    Biogerontology 9:299-308. 2008
    ..These results highlight the importance of functioning of the thymus in the development of IRP and may partly account for the differences between sexes in terms of longevity...
  73. ncbi A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer
    Alfred E Chang
    Department of Surgery, University of Michigan, Ann Arbor, Michigan 48109 0932, USA
    Clin Cancer Res 8:1021-32. 2002
    ..The objectives of this study were to assess the toxicity and immunological response induced by the intradermal (i.d) administration of tumor lysate-pulsed dendritic cells (DCs)...
  74. ncbi Performance of the Panleucogating protocol for CD4+ T cell enumeration in an HIV dedicated laboratory facility in Barbados
    Namrata Sippy-Chatrani
    Ladymeade Reference Unit, Ministry of Health, Barbados, West Indies
    Cytometry B Clin Cytom 74:S65-8. 2008
    ..To compare the Panleucogating (PLG) protocol with the routinely used four-color protocol for CD4+ T cell count enumeration...
  75. ncbi Immunological monitoring of cancer vaccine therapy
    Dirk Nagorsen
    Charite, Campus Benjamin Franklin, Medizinische Klinik III, Hindenburgdamm 30, 12200 Berlin, Germany
    Expert Opin Biol Ther 4:1677-84. 2004
    ....
  76. ncbi [Microbiological and immunological monitoring in polyarticular rheumatoid arthritis after total joint replacement]
    D Kunz
    Institut fur Medizinische Mikrobiologie, Universitätsklinikum der Otto von Guericke Universität Magdeburg
    Dtsch Med Wochenschr 126:138-40. 2001
    ....
  77. ncbi American Association for Cancer Research: Clinical trials of immunotherapeutics and immunologic monitoring. April 1-5, 2000, San Francisco, CA, USA
    M L Salgaller
    Antigen Research and Development Division, Northwest Biotherapeutics, Inc, Seattle, WA 98134, USA
    Expert Opin Investig Drugs 9:1413-7. 2000
    ..Others discussed ways in which those in the immunotherapy community can work towards more reliable immune monitoring and ultimately a surrogate marker for response...
  78. ncbi Emergence of BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during long-term imatinib mesylate treatment
    Giovanni Riva
    Section of Hematology, Department of Oncology, Hematology and Respiratory Diseases, University of Modena and Reggio Emilia, Via del Pozzo 71, Modena, Italy
    Blood 115:1512-8. 2010
    ..Whether these autologous (p190)BCR-ABL-specific T cells may be detectable under other tyrosine-kinase inhibitors, expanded ex vivo, and exploited for immunotherapy remains to be addressed...
  79. pmc His-tag ELISA for the detection of humoral tumor-specific immunity
    Vivian Goodell
    Center for Translational Medicine in Women s Health, University of Washington, Seattle, WA 98109 8050, USA
    BMC Immunol 9:23. 2008
    ..As newly identified antigens are incorporated into a variety of clinical trials, standardization of immunologic monitoring methods becomes increasingly important...
  80. ncbi Melanoma cancer vaccines and anti-tumor T cell responses
    Lazar Vujanovic
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pennsylvania 15213, USA
    J Cell Biochem 102:301-10. 2007
    ....
  81. ncbi CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT
    M Kapp
    Medizinische Klinik und Poliklinik II, Julius Maximilians Universitat, Wurzburg, Germany
    Bone Marrow Transplant 43:399-410. 2009
    ..new peptide epitopes from the MUC1 Ag to broaden patients' screening and to expand the repertoire of immunologic monitoring as well as for therapeutic approaches in the future...
  82. ncbi Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy
    G Brestrich
    Department of Nephrology and Internal Intensive Care, Universitatsmedizin, Berlin, Germany
    Am J Transplant 9:1679-84. 2009
    ..Further studies have to elucidate the most potent strategies to generate antigen-specific T cells with high functional capacity and robust long-term persistence...
  83. pmc Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes
    V A L Huurman
    Department of Immunohematology and Blood Transfusion, and Surgery, Leiden University Medical Center, Leiden, The Netherlands
    Clin Exp Immunol 152:488-97. 2008
    ..Declining or temporary proliferative responses to peptide DiaPep277 treatment may serve as an immunological biomarker for clinical efficacy...
  84. ncbi Intravenous immune globulin in symptomatic paediatric human immunodeficiency virus infection
    U B Schaad
    Department of Paediatrics, University of Berne, Inselspital, Switzerland
    Eur J Pediatr 147:300-3. 1988
    ..The immunologic monitoring revealed some discrete objective improvements...
  85. ncbi Functional genomic analysis of peripheral blood during early acute renal allograft rejection
    Oliver P Günther
    PROOF Centre of Excellence, University of British Columbia, Vancouver, BC V5Z 1M9, Canada
    Transplantation 88:942-51. 2009
    ....
  86. ncbi Hematopoietic growth factors, dendritic cell biology, and vaccine therapy of cancer
    Joseph W Fay
    Immunologic Therapy for Cancer, Baylor Institute for Immunology Research, Baylor University Medical Center, Dallas, Texas 75247, USA
    Curr Opin Hematol 9:202-6. 2002
    ..to immune effector cells, dendritic cell maturation, the route of dendritic cell administration to humans, and immunologic monitoring are parameters that require vigorous study in the context of dendritic cell immunotherapy of cancer.
  87. ncbi Bronchoscopic monitoring after lung transplantation
    Allan R Glanville
    The Lung Transplant Unit, St Vincent s Hospital, Darlinghurst, NSW, Australia
    Semin Respir Crit Care Med 31:208-21. 2010
    ..This review examines the role of fiberoptic bronchoscopy after LT as a surveillance tool versus a clinically mandated diagnostic procedure...
  88. ncbi Considerations on clinical use of T cell immunotherapy for cancer
    Gregory E Plautz
    Center for Surgery Research, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Arch Immunol Ther Exp (Warsz) 51:245-57. 2003
    ..b>Immunologic monitoring of vaccinated patients has demonstrated an expansion of CD8+ T cells that react with the relevant peptide ..
  89. pmc Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda
    Steven J Reynolds
    National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA
    AIDS 23:697-700. 2009
    ..Our objective was to evaluate immunologic failure criteria against gold standard virologic monitoring...
  90. ncbi IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC
    Gordana Konjevic
    Department of Experimental Immunology, Institute for Oncology and Radiology of Serbia, Belgrade, Yugoslavia
    Clin Exp Metastasis 20:647-55. 2003
    ....
  91. ncbi Cultures of aspiration biopsy specimens in the immunological monitoring of renal transplants
    G Oliveira
    Renal Department, H S João, Porto, Portugal
    Nephron 76:310-4. 1997
    ..Our aim was to study GIC harvested by fine-needle aspiration biopsy (FNAB) in renal transplant recipients...
  92. ncbi Genotypic resistance and the treatment of HIV-1 infection in Espírito Santo, Brazil
    C D Pilcher
    Division of Infectious Diseases, Department of Medicine, University of North Carolina Chapel Hill, Chapel Hill, NC 27599 7030, USA
    J Infect Dis 179:1259-63. 1999
    ..1997, in Espírito Santo, Brazil, combination antiretroviral therapy was used without routine virologic or immunologic monitoring. To examine consequences of therapy in this setting, clinical information, human immunodeficiency virus ..
  93. ncbi A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients
    Ryan D Cassaday
    Paul P Carbone Comprehensive Cancer Center, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, USA
    Clin Cancer Res 13:540-9. 2007
    ..The aims of this phase I study were to assess the safety and immunologic effects of PMED of these genes in melanoma patients...
  94. pmc CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
    Jianda Yuan
    Ludwig Center for Cancer Immunotherapy, Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 105:20410-5. 2008
    ..Fifteen patients were selected on the basis of availability of suitable specimens for immunologic monitoring, and eight of these showed evidence of clinical benefit...
  95. ncbi The immunological monitoring of alloreactive responses in liver transplant recipients: a review
    Raymond Reding
    Pediatric Liver Transplant Program, Saint Luc University Clinics, Universite Catholique de Louvain, Brussels, Belgium
    Liver Transpl 12:373-83. 2006
    ..A conceptual framework for the development of tolerance assays in clinical liver transplantation is also proposed...
  96. ncbi Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria
    Joep J G van Oosterhout
    Department of Medicine, University of Malawi College of Medicine, Blantyre, Malawi
    Trop Med Int Health 14:856-61. 2009
    ..We wanted to study the impact of only using clinical and immunological monitoring on the diagnosis of virological ART failure under routine circumstances...
  97. ncbi Metastable tolerance in nonhuman primates and humans
    Stuart J Knechtle
    Division of Transplantation, Department of Surgery, University of Wisconsin Medical School, Madison, WI 53792 7375, USA
    Transplantation 77:936-9. 2004
    ..drugs and establish a tolerant state will depend importantly on development of such diagnostic immunologic monitoring tools...
  98. ncbi Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope
    Satoko Morishima
    Division of Immunology, Aichi Cancer Center Research Institute, Nagoya, Japan
    Int J Cancer 120:594-604. 2007
    ..Thus, these findings together indicate that E6(49-57) is a candidate epitope for immunotherapy and immunological monitoring of such patients...
  99. ncbi [Economic burden and clinical course of HIV infection and AIDS today: how the variation of natural history, available treatments, and strictly related costs play a role in needs of health care]
    R Manfredi
    Sezione di Malattie Infettive, Dipartimento di Medicina Clinica Specialistica e Sperimentale, Università Alma Mater, Azienda Ospedaliera Policlinico S Orsola Malpighi, Bologna
    Recenti Prog Med 92:648-54. 2001
    ....
  100. ncbi Sustained immunological responses to highly active antiretroviral therapy at 36 months in a Ghanaian HIV cohort
    Paul Collini
    School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, United Kingdom
    Clin Infect Dis 48:988-91. 2009
    ..However, two-thirds of patients who experienced immunological failure did not switch treatment, and 31% of all patients were lost to follow-up...
  101. ncbi Molecular tracking of antigen-specific T-cell clones during immune responses
    Nathalie Rufer
    Swiss Institute for Experimental Cancer Research ISREC, NCCR Molecular Oncology, 155 ch des Boveresses, CH 1066 Epalinges, Switzerland
    Curr Opin Immunol 17:441-7. 2005
    ..During the past few years, highly sensitive tools have been developed to enable the molecular dissection and tracking of clonal T-cell expansion in animal models as well as in humans...

Research Grants62

  1. Phase I Trial with Two HER-2 B Cell Epitope Vaccine in Patients with Solid Tumors
    PRAVIN T P contact KAUMAYA; Fiscal Year: 2010
    ..The advantage of active immunotherapy with safe and non toxic natural synthetic peptides over passive immunotherapy with mAbs such as trastuzumab (Herceptin) is a fundamental aspect of this work. ..
  2. Immunoregulation and immunotherapy of breast cancer
    Robert H Vonderheide; Fiscal Year: 2012
    ..The long-term goal is to develop an immune-based therapy that offers clinical benefit to patients with hormone receptor positive breast cancer. ..
  3. Novel Strategies for Brain Tumor Therapy
    Ian F Pollack; Fiscal Year: 2012
    ....
  4. Eastern Cooperative Oncology Group (Main Institution)
    JOHN MUNN KIRKWOOD; Fiscal Year: 2013
    ..Those that relate directly to ECOG include the Clinical Immunologic Monitoring Laboratory (IMCPL) which serves as the Core Immunological Monitoring Laboratory for ECOG, the Serum and ..
  5. SPORE in Skin Cancer
    JOHN MUNN KIRKWOOD; Fiscal Year: 2013
    ..The Biospecimen Core (B) is housed in the UPCI Immunologic Monitoring and Cellular Products Laboratory, where all tissue banking, biospecimen processing, and immune assays are ..
  6. CANCER CENTER SUPPORT GRANT
    Michelle M Le Beau; Fiscal Year: 2013
    ..resources (Biostatistics;Cancer Clinical Trials Office;Cytometry and Antibody Technology;Genomics;Human Immunologic Monitoring and cGMP;Human Tissue Resource Center;Image Computing, Analysis, and Repository;Integrated Microscopy;..
  7. DISSECTING THE IMMUNE BASIS OF DISEASE AND THERAPY
    Nitin J Karandikar; Fiscal Year: 2013
    ..will apply current knowledge about the MS immune system to develop a diagnostic laboratory test for the immunologic monitoring of this disease...
  8. Host-tumor cell interaction in myeloma: therapeutic applications
    Kenneth C Anderson; Fiscal Year: 2013
    ..Ultimately, our goal is to validate MM-host cell interactions as a target for novel therapeutics to improve patient outcome in MM. ..
  9. Stem Cell-Engineered Tumor Immunity in Man
    David Baltimore; Fiscal Year: 2013
    ..abstract_text> ..
  10. Predicting immune responses that correlate with protection against tuberculosis
    JENNIFER JEAN LINDERMAN; Fiscal Year: 2013
    ..effective (resulting in protected and non-protected animals), and state-of- the-art live animal imaging, immunologic monitoring, and computational models, to identify and predict the immunologic mechanisms that are protective against ..
  11. Pilot trial of a DNA vaccine encoding PAP in patients with prostate cancer
    Douglas McNeel; Fiscal Year: 2009
    ..This is consequently relevant to the development of other anti-tumor vaccines. ..
  12. Case AIDS Clinical Trials Unit
    MICHAEL MARCEL LEDERMAN; Fiscal Year: 2013
    ..Established scientific strengths of the unit have been in the arenas of immunologic monitoring, vaccine and other immune based therapeutic studies, studies of hepatitis C infection and of the metabolic ..
  13. Case AIDS Clinical Trials Unit
    MICHAEL MARCEL LEDERMAN; Fiscal Year: 2011
    ..Established scientific strengths of the unit have been in the arenas of immunologic monitoring, vaccine and other immune based therapeutic studies, studies of hepatitis C infection and of the metabolic ..
  14. Peptide vaccine-based immunotherapy for children with recurrent ependymomas.
    Ian F Pollack; Fiscal Year: 2013
    ..These studies take advantage of unique institutional resources provided by our Immunologic Monitoring Laboratory, which are integrated into the clinical trial...
  15. RENAL TRANSPLANT ENHANCEMENT BY DONOR SPECIFIC BLOOD
    Charles Anderson; Fiscal Year: 1992
    ..Recipients will undergo immunologic monitoring by: T- and B-cell crossmatch, mixed leukocyte reaction (MLR), antiidiotypic antibody analysis, interleukin ..
  16. PEPTIDE-PULSED DENDRITIC CELL THERAPY FOR MELANOMA
    Frank Haluska; Fiscal Year: 2000
    ..Rigorous immunologic monitoring will be carried out...
  17. SRC on Primary Tumors of the CNS
    Darell D Bigner; Fiscal Year: 2013
    ..an IND, Regulatory, and Bioinformatics Core (Core A);a Brain Tumor Biorepository, Histopathology, and Immunologic Monitoring Core (Core B), and an Administrative Core (Core C)...
  18. Allogeneic Stem Cell Transplants for HPV+Cervical Cancer
    Alexander Fefer; Fiscal Year: 2003
    ..the safety, c) monitor hematopoietic engraftment and lymphoid chimerism, and d) determine by concurrent immunologic monitoring whether T cells from the normal ste cell donors can acquire HPVE6/E7-specific reactivity in vivo or in ..
  19. AFP-Based Immunotherapy for Hepatocellular Carcinoma
    Antoni Ribas; Fiscal Year: 2006
    ..In summary, I propose a clinically-oriented research program that translates this original work into novel, evidence-based immnunotherapy trials for hepatocellular carcinoma. ..
  20. MIAMI ADULT AIDS CLINICAL TRIALS GROUP, AACTG
    Margaret Fischl; Fiscal Year: 2006
    ..and treatment and peripheral neuropathy pain assessment, Kaposi sarcoma (KS) pathogenesis, intensive immunologic monitoring and definition, and validation of immunologic determinants of treatment response...
  21. Conference Proposal: Transplantation Immunology
    Angus Thomson; Fiscal Year: 2004
    ..of vascular and parenchymal inflammation; 7) stem cells/tissue engineering and 8) novel technologies/immunologic monitoring. An important aspect of this conference will be the interaction between scientists with expertise in basic ..
  22. Melanoma Vaccines with Peptides, Protein and Adjuvant
    Hassane Zarour; Fiscal Year: 2009
    ..expected to stimulate plasmacytoid dendritic cells (PDCs) resulting in strong Th1-type immunity;(4) modern immunologic monitoring techniques will allow us to discriminate melanoma-specific T cell responses in the blood of vaccinated ..
  23. MAGE-A3/HPV 16 Peptide Vaccines for Head and Neck Cancer
    Scott Strome; Fiscal Year: 2006
    ..Additionally, a paucity of antigenic peptide epitopes are defined for SCCHN, and immunologic monitoring does not correlate well with clinical response...
  24. GENE THERAPY OF CANCER-IMMUNOLOGICAL APPROACHES
    MICHAEL LOTZE; Fiscal Year: 1993
    ..these projects as well as three cores (Administrative core, Vector core, and Immunologic Monitoring and Cellular Therapy Core) represent a focused and integrated approach to using gene therapies to enhance ..
  25. Immunological Monitoring of Heart Allograft Recipients
    Nicole Suciu Foca; Fiscal Year: 2006
    ....
  26. PROSTAGLANDINS AND RENAL ALLOGRAFT REJECTION
    Charles Anderson; Fiscal Year: 1990
    ..Concomitant immunologic monitoring of T- lymphocyte function in the renal allograft, spleen, and blood will be performed by one way mixed ..
  27. ANCHOR MODIFIED PEPTIDES FOR IMMUNIZATION IN MELANOMA
    Gerald Linette; Fiscal Year: 2002
    ..is built upon the premise that delivery of an immunogenic peptide vaccine with subsequent intensive immunologic monitoring is required to optimally elicit an effective T cell response capable of eradicating residual tumor...
  28. CYTOKINE GENE THERAPY OF CANCER
    Walter Storkus; Fiscal Year: 2001
    ..These include: Administrative Core, (Michael T. Lotze, MD); Immunologic Monitoring and Diagnostic Laboratory Core (IMDL), (Theresa L...
  29. IMMUNOTHERAPY OF PROSTATE CANCER WITH TUMOR VACCINES
    Johannes Vieweg; Fiscal Year: 2001
    ..abstract_text> ..
  30. U. of Wisconsin Transplant Research Training Program
    Stuart Knechtle; Fiscal Year: 2006
    ....
  31. Campath-1H & Calcineurin-Inhibitors in Renal Transplant
    Stuart Knechtle; Fiscal Year: 2007
    ..assays would be applicable to a broad range of organ transplant recipients and would guide development of immunologic monitoring tools in the field of transplantation. The four specific aims of this application are: 1...
  32. TRANSPLANTATION TOLERANCE USING IMMUNOTOXIN
    Stuart Knechtle; Fiscal Year: 2001
    ..The goal of this proposal would be to develop adequate preclinical data to permit phase I and II clinical trials in organ transplant recipients. ..
  33. Renal Transplantation Using Campath1H/Rapamycin
    Stuart Knechtle; Fiscal Year: 2003
    ..This data will be correlated with histopathology of protocol biopsies. ..
  34. CXCR3 Chemokine Receptor in Non-Human Primate Allograft
    Stuart Knechtle; Fiscal Year: 2006
    ..We plan to take advantage of the combined experience of the Hancock and Knechtle labs to address the research questions posed herein. ..
  35. COLUMBIA-ADARC-CORNELL AIDS CLINICAL TRIALS UNIT
    Scott Hammer; Fiscal Year: 2006
    ..Thus, the Columbia-ADARC ACTU will be an active participant in the Group's mission to improve the health of HIV infected individuals and set standards for treatment of HIV disease. ..
  36. VACCINES WITH MHC CLASS II-RESTRICTED MELANOMA PEPTIDES
    Craig Slingluff; Fiscal Year: 2004
    ....
  37. RESEARCH TRAINING IN TRANSLATIONAL TUMOR IMMUNOLOGY
    Alfred Chang; Fiscal Year: 2005
    ..Predoctoral and postdoctoral trainees should leave the program well prepared for academic careers focused on translational aspects of immunologic research as it pertains to the development of new strategies for the treatment of cancer. ..
  38. Cellular Immunity to BK Virus
    Simon Lacey; Fiscal Year: 2005
    ..Such information may be useful in guiding clinical management, and lay the foundation for possible future vaccines. ..
  39. MULTI-EPITOPE MELANOMA PEPTIDE VACCINATION WITH GM-CSF
    Craig Slingluff; Fiscal Year: 2004
    ..abstract_text> ..
  40. MIDCAREER INVESTIGATOR AWARD IN PATIENT ORIENTED RESEARC
    MARY DISIS; Fiscal Year: 2004
    ....
  41. Multi-Antigen Vaccines for Breast Cancer
    MARY DISIS; Fiscal Year: 2007
    ..abstract_text> ..
  42. Beta-B1 Crystallin - a New Candidate Uveitis Autoantigen
    Lynn Gordon; Fiscal Year: 2003
    ..abstract_text> ..
  43. CD1D REACTIVE T CELLS IN BONE MARROW TRANSPLANTATION
    Mark Exley; Fiscal Year: 2002
    ..These preclinical studies are necessary to evaluate the hypothesis that human CD1d-reactive T cells have the therapeutic potential to selectively suppress acute GvH in the context of conventional BM and PBPC transplants for cancer. ..
  44. RHESUS MACAQUE MODEL OF TUBERCULOSIS
    DAVID LEWINSOHN; Fiscal Year: 2001
    ..g., CT scans, quantitative culture of mycobacteria from BAL fluids and liver biopsies) which correlate with survival. ..
  45. T Cell Immunotherapy of Pediatric Brain Tumors
    GREGORY PLAUTZ; Fiscal Year: 2005
    ..Alternatively if cross -reactive glioma Ags are identified it would stimulate future studies for molecular characterization of the antigens and provide the rationale for development of a uniform glioma vaccine. ..
  46. Multi-peptide Vaccine Administered with Cyclophosphamide for High-risk Melanoma
    CRAIG LEE SLINGLUFF; Fiscal Year: 2010
    ....
  47. Phase I Trial of a HER2 ICD Plasmid-Based DNA Vaccine
    MARY DISIS; Fiscal Year: 2007
    ..The long-term goal will be to use this study as a platform to develop multi-antigen plasmid based vaccines for the prevention of common solid tumors. ..
  48. T CELL THERAPY OF HUMAN RENAL CELL CANCER
    Alfred Chang; Fiscal Year: 2007
    ..Lloyd Stoolman. Dr. Stoolman plans to examine novel methods to enrich tumor reactive lymphoid cells based upon adhesion marker expansion utilizing samples generated from this proposal. ..
  49. Noninvasive biomarkers of proteolytic activity in CF
    Scott Sagel; Fiscal Year: 2007
    ..In addition, he will actively participate and train in the Pediatric GCRC, and frequently interact with his sponsor, mentors, and collaborators. ..
  50. 2007 Antigen Cross-Presentation
    Pramod Srivastava; Fiscal Year: 2007
    ..In all cases, we attempt to bridge the gap between researchers addressing[unreadable] questions using reductionist model systems with clinicians working at the bedside of patients. ..
  51. Analysis of serum folate receptor and antibody level for ovarian cancer detection
    Keith Knutson; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  52. Criteria for Protective Immunity to BK virus in Kidney Transplant Recipients
    Simon Lacey; Fiscal Year: 2007
    ..Information from the proposed study may allow identification of patients at risk of progression from BKV reactivation to clinical BKV disease and guide therapeutic interventions. [unreadable] [unreadable] [unreadable]..
  53. TLR-mediated DC activation and immune reconstitution
    Hong Ming Hu; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  54. T CELL ACTIVATION FOR CANCER IMMUNOTHERAPY
    Alfred Chang; Fiscal Year: 2008
    ..We have extensive experience in the conduct of adoptive immunotherapy and vaccine trials in humans that will allow translation of these findings. ..
  55. Targeted Molecular Therapeutics for Melanoma: CCI-779 and Bevacizumab
    Craig Slingluff; Fiscal Year: 2008
    ..The following proposal is a clinical trial to evaluate the effects of bevacizumab and CCI-779, which interfere with vascularization and tumor growth, for the treatment of melanoma. [unreadable] [unreadable] [unreadable]..
  56. Innate-like hepatic CD1d-reative NKT cells:Liver Disease
    Mark Exley; Fiscal Year: 2008
    ..I. on acute HCV infection in chimpanzees, as well as on liver immunology and on 'NKT' cells in general. ..
  57. Ex vivo expansion of HER-2/neu specific T helper cells
    Keith Knutson; Fiscal Year: 2008
    ..abstract_text> ..
  58. Immunologic Correlates of Immunization for Cancer
    MARY DISIS; Fiscal Year: 2006
    ..abstract_text> ..
  59. Immune Response to Polyomavirus Infection
    Parmjeet S Randhawa; Fiscal Year: 2010
    ..This, in turn, will help us to better predict the clinical course of the disease in individual patients, and help devise more effective forms of anti-viral therapy. ..
  60. Mechanisms of immunomodulatory and anti-tumor actions of Polysaccharide Krestin
    Mary L Disis; Fiscal Year: 2010
    ..Results from these studies will help us understand the immune modulating effect of PSK and contribute to the clinical translation of this CAM molecule as an anti-cancer agent and/or a vaccine adjuvant. ..